ArticleBiochemical and biophysical research communications2009
Motor neuronal protection by L-arginine prolongs survival of mutant SOD1 (G93A) ALS mice.
Article in Biochemical and biophysical research communications, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 44 citations in OpenAlex.
- Trial
- Axonal Eif5a hypusination controls local translation and mitigates defects in FUS-ALS.Nature neuroscience · 2026Article
- Metabolic dysregulation in amyotrophic lateral sclerosis: insights fromMetabolic brain disease · 2025Article
- Effect of Various Pathological Conditions on Nitric Oxide Level and L-Citrulline Uptake in Motor Neuron-Like (NSC-34) Cell Lines.Biomolecules & therapeutics · 2024Article
- Swimming and L-arginine loaded chitosan nanoparticles ameliorates aging-induced neuron atrophy, autophagy marker LC3, GABA and BDNF-TrkB pathway in the spinal cord of rats.Pflugers Archiv : European journal of physiology · 2023Article
- A Glutamate Scavenging Protocol Combined with Deanna Protocol in SOD1-G93A Mouse Model of ALS.Nutrients · 2023Article
- Modulation of histone H3K4 dimethylation by spermidine ameliorates motor neuron survival and neuropathology in a mouse model of ALS.Journal of biomedical science · 2022Article
- Blood-Brain Barrier Solute Carrier Transporters and Motor Neuron Disease.Pharmaceutics · 2022Review
- Antioxidant and Neuroprotective Effects of Paeonol against Oxidative Stress and Altered Carrier-Mediated Transport System on NSC-34 Cell Lines.Antioxidants (Basel, Switzerland) · 2022Article
- Preclinical investigation of Pegylated arginase 1 as a treatment for retina and brain injury.Experimental neurology · 2022Article
- Article
- L-Citrulline Level and Transporter Activity Are Altered in Experimental Models of Amyotrophic Lateral Sclerosis.Molecular neurobiology · 2021Article
- Untargeted metabolomics yields insight into ALS disease mechanisms.Journal of neurology, neurosurgery, and psychiatry · 2020Article
- Small Molecules Attenuate the Interplay between Conformational Fluctuations, Early Oligomerization and Amyloidosis of Alpha Synuclein.Scientific reports · 2018Article
- Astrocytes and Microglia as Non-cell Autonomous Players in the Pathogenesis of ALS.Experimental neurobiology · 2016Review
- A(a)LS: Ammonia-induced amyotrophic lateral sclerosis.F1000Research · 2015Article
- Regulation of CuZnSOD and its redox signaling potential: implications for amyotrophic lateral sclerosis.Antioxidants & redox signaling · 2014Review
- Microglia and motor neurons during disease progression in the SOD1G93A mouse model of amyotrophic lateral sclerosis: changes in arginase1 and inducible nitric oxide synthase.Journal of neuroinflammation · 2014Article
- Expression of taurine transporter (TauT) is modulated by heat shock factor 1 (HSF1) in motor neurons of ALS.Molecular neurobiology · 2013Article
- Differential expression of c-Ret in motor neurons versus non-neuronal cells is linked to the pathogenesis of ALS.Laboratory investigation; a journal of technical methods and pathology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive paralysis due to motor neuron degeneration. Despite the fact that many different therapeutic strategies have been applied to prevent disease progression, no cure or effective therapy is currently available for ALS. We found that L-arginine protects cultured motor neurons from excitotoxic injury. We also found that L-arginine supplementation both prior to and after the onset of motor neuron degeneration in mtSOD1 (G93A) transgenic ALS mice significantly slowed the progression of neuropathology in lumbar spinal cord, delayed onset of motor dysfunction, and prolonged life span. Moreover, L-arginine treatment was associated with preservation of arginase I activity and neuroprotective polyamines in spinal cord motor neurons. Our findings show that L-arginine has potent in vitro and in vivo neuroprotective properties and may be a candidate for therapeutic trials in ALS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.